Jean Jacques Bienaime - 30 Apr 2021 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
30 Apr 2021
Net transactions value
-$2,564,539
Form type
4
Filing time
10 May 2021, 21:07:55 UTC
Next filing
12 May 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $21,281 +341 +0.11% $62.41 303,839 30 Apr 2021 Direct F1
transaction BMRN Common Stock Options Exercise $662,250 +25,000 +8.2% $26.49 328,839 06 May 2021 Direct F2
transaction BMRN Common Stock Sale $1,156,528 -14,825 -4.5% $78.01 314,014 06 May 2021 Direct F2, F3
transaction BMRN Common Stock Sale $800,671 -10,175 -3.2% $78.69 303,839 06 May 2021 Direct F2, F4
transaction BMRN Common Stock Options Exercise $662,250 +25,000 +8.2% $26.49 328,839 07 May 2021 Direct F2
transaction BMRN Common Stock Sale $1,207,146 -15,556 -4.7% $77.60 313,283 07 May 2021 Direct F2, F5
transaction BMRN Common Stock Sale $481,672 -6,115 -2% $78.77 307,168 07 May 2021 Direct F2, F6
transaction BMRN Common Stock Sale $264,303 -3,329 -1.1% $79.39 303,839 07 May 2021 Direct F2, F7, F8
holding BMRN Common Stock 247,533 30 Apr 2021 Shares held by Jean-Jacques Bienaime Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -25,000 -43% $0.000000 33,513 06 May 2021 Common Stock 25,000 $26.49 Direct F2, F9
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -25,000 -75% $0.000000 8,513 07 May 2021 Common Stock 25,000 $26.49 Direct F2, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired by the reporting person on April 30, 2021, pursuant to the issuer's Employee Stock Purchase Plan.
F2 Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021.
F3 The price in column 4 is the weighted average price. The price actually received ranged from $77.375 to $78.37. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F4 The price in column 4 is the weighted average price. The price actually received ranged from $78.38 to $78.99. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F5 The price in column 4 is the weighted average price. The price actually received ranged from $77.13 to $77.95. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F6 The price in column 4 is the weighted average price. The price actually received ranged from $78.15 to $79.14. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F7 The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $77.9400 on March 4, 2021. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
F8 The price in column 4 is the weighted average price. The price actually received ranged from $79.15 to $79.75. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F9 Reflects the number of options outstanding after the transactions from this specific stock option grant.